Read More Pharma Industry News How SC-dosed NK cell engagers like GTB-5550 could disrupt cancer care delivery models GT Biopharma’s GTB-5550 receives FDA clearance with subcutaneous delivery. See how this trial could shift NK immunotherapy into outpatient cancer care. bySoujanya RaviFebruary 6, 2026